Synaptiq Therapeutics Launches with Acquisition of Clinical-Stage SYN-001 Program

Phase 2SYN-001Positive

AI Analysis

Summary

Synaptiq Therapeutics was formed to advance SYN-001, an orphan and rare pediatric disease therapeutic candidate acquired from Nobias Therapeutics. A Phase IIb trial is planned to evaluate SYN-001 for treating neuropsychiatric symptoms associated with 22q11.2 Deletion Syndrome.

Clinical Trial Data

Phase

IIb

Outcome Details

Phase IIb trial planned to further evaluate SYN-001

Importance:5/10

Sentiment:

0.60

company_formationacquisitionclinical_developmentorphan_drugrare_pediatric_diseaseneuropsychiatric

Read the original article

Published by PR Newswire Biotech on July 23, 2026 12:56 PM

Read Original